The FDA and Novo Nordisk are warning consumers, pharmacies, and healthcare professionals about counterfeit Ozempic® (semaglutide) 1 mg injection found in the U.S. drug supply chain. Several hundred counterfeit units were distributed outside of Novo Nordisk’s authorized supply chain. The FDA seized the affected products on April 9, 2025, and an investigation is ongoing.

The seized counterfeits are labeled with lot number PAR0362 and serial numbers beginning with 51746517. While PAR0362 is an authentic lot number, the combination of this lot number with the listed serial digits indicates a counterfeit product. The identity, quality, and safety of the seized products have not been confirmed and may pose a health risk.

What to Do:

• Patients and pharmacies should verify their Ozempic® 1 mg products and avoid using or distributing any product with the identifiers above.
• Concerns or questions about product authenticity can be directed to Novo Nordisk Customer Care at 1-800-727-6500 (Mon–Fri, 8:30 AM–6:00 PM EST).
• Suspected counterfeit products should also be reported to the FDA at Report Suspected Criminal Activity.

For more information, visit FDA or Novo Nordisk US.